669 related articles for article (PubMed ID: 24837480)
21. Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease.
Simile MM; Latte G; Demartis MI; Brozzetti S; Calvisi DF; Porcu A; Feo CF; Seddaiu MA; Daino L; Berasain C; Tomasi ML; Avila MA; Feo F; Pascale RM
Oncotarget; 2016 Aug; 7(31):49194-49216. PubMed ID: 27359056
[TBL] [Abstract][Full Text] [Related]
22. Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma.
Molina L; Bell D; Tao J; Preziosi M; Pradhan-Sundd T; Singh S; Poddar M; Luo J; Ranganathan S; Chikina M; Monga SP
Am J Pathol; 2018 Aug; 188(8):1895-1909. PubMed ID: 29920228
[TBL] [Abstract][Full Text] [Related]
23. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer.
Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L
Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.
Zhang T; Zhang J; You X; Liu Q; Du Y; Gao Y; Shan C; Kong G; Wang Y; Yang X; Ye L; Zhang X
Hepatology; 2012 Dec; 56(6):2051-9. PubMed ID: 22707013
[TBL] [Abstract][Full Text] [Related]
25. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
26. TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.
Zhang J; Liu P; Tao J; Wang P; Zhang Y; Song X; Che L; Sumazin P; Ribback S; Kiss A; Schaff Z; Cigliano A; Dombrowski F; Cossu C; Pascale RM; Calvisi DF; Monga SP; Chen X
Am J Pathol; 2019 May; 189(5):1077-1090. PubMed ID: 30794805
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
28. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis.
Rosenbluh J; Nijhawan D; Cox AG; Li X; Neal JT; Schafer EJ; Zack TI; Wang X; Tsherniak A; Schinzel AC; Shao DD; Schumacher SE; Weir BA; Vazquez F; Cowley GS; Root DE; Mesirov JP; Beroukhim R; Kuo CJ; Goessling W; Hahn WC
Cell; 2012 Dec; 151(7):1457-73. PubMed ID: 23245941
[TBL] [Abstract][Full Text] [Related]
29. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma.
Guo C; Zhou S; Yi W; Yang P; Li O; Liu J; Peng C
Exp Mol Pathol; 2021 Jun; 120():104638. PubMed ID: 33878313
[TBL] [Abstract][Full Text] [Related]
31. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
[TBL] [Abstract][Full Text] [Related]
32. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
33. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin.
Asayama Y; Taguchi Ki K; Aishima Si S; Nishi H; Masuda K; Tsuneyoshi M
Liver; 2002 Feb; 22(1):43-50. PubMed ID: 11906618
[TBL] [Abstract][Full Text] [Related]
34. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
Carotenuto P; Fassan M; Pandolfo R; Lampis A; Vicentini C; Cascione L; Paulus-Hock V; Boulter L; Guest R; Quagliata L; Hahne JC; Ridgway R; Jamieson T; Athineos D; Veronese A; Visone R; Murgia C; Ferrari G; Guzzardo V; Evans TRJ; MacLeod M; Feng GJ; Dale T; Negrini M; Forbes SJ; Terracciano L; Scarpa A; Patel T; Valeri N; Workman P; Sansom O; Braconi C
Gut; 2017 Jul; 66(7):1268-1277. PubMed ID: 27618837
[TBL] [Abstract][Full Text] [Related]
35. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance.
Zhou D; Zhang Y; Wu H; Barry E; Yin Y; Lawrence E; Dawson D; Willis JE; Markowitz SD; Camargo FD; Avruch J
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1312-20. PubMed ID: 22042863
[TBL] [Abstract][Full Text] [Related]
36. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
Lim K; Han C; Xu L; Isse K; Demetris AJ; Wu T
Cancer Res; 2008 Jan; 68(2):553-60. PubMed ID: 18199552
[TBL] [Abstract][Full Text] [Related]
37. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
38. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.
Tschaharganeh DF; Chen X; Latzko P; Malz M; Gaida MM; Felix K; Ladu S; Singer S; Pinna F; Gretz N; Sticht C; Tomasi ML; Delogu S; Evert M; Fan B; Ribback S; Jiang L; Brozzetti S; Bergmann F; Dombrowski F; Schirmacher P; Calvisi DF; Breuhahn K
Gastroenterology; 2013 Jun; 144(7):1530-1542.e12. PubMed ID: 23419361
[TBL] [Abstract][Full Text] [Related]
39. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
[TBL] [Abstract][Full Text] [Related]
40. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
